Compound Detail
CHEMBL441
THIOPENTAL 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Basic Information
| ChEMBL ID | CHEMBL441 |
| Name | THIOPENTAL |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | IUJDSEJGGMCXSG-UHFFFAOYSA-N |
| Therapeutic | ✓ Yes |
2
Targets
3
Activities
1
Assay Types
14
PK Parameters
20
Publications
2
Known Names
4
Indications
Molecular Properties
242.3
MW (Da)
1.35
ALogP
3
HBA
2
HBD
58.2
PSA (Ų)
0.58
QED
0
Ro5 Violations
4
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 1982 |
| Availability | Discontinued |
| Chirality | Racemic |
Indications
Brain Injuries Shock, Septic Status Epilepticus Strabismus
ATC Classification
N01AF03
thiopental
Level 1: NERVOUS SYSTEM
Level 2: ANESTHETICS
N05CA19
thiopental
Level 1: NERVOUS SYSTEM
Level 2: PSYCHOLEPTICS
Activity Summary
IC50 3 meas. best 6.55
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Voltage-dependent L-type calcium channel subunit alpha-1C CHEMBL2366456 | IC50 | 6.55 | 6.55 | 280.0 | 1 |
| GABA-A receptor; anion channel CHEMBL1907607 | IC50 | 4.53 | 4.53 | 29500.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| AUC | 215.0 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | 209.0 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | 16.6 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | 16.4 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | 244.0 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | 216.0 | ng.hr.mL-1 | Rattus norvegicus |
| CL | 8.2 | mL.min-1.kg-1 | Homo sapiens |
| CL | 8.2 | mL.min-1.kg-1 | Homo sapiens |
| Fu | 0.14 | - | Homo sapiens |
| Fu | 0.19 | - | Rattus norvegicus |
| Fu | 0.16 | - | Rattus norvegicus |
| MRT | 2.4 | hr | Homo sapiens |
| T1/2 | 2.0 | hr | Homo sapiens |
| Vd | 4.3 | L.kg-1 | Rattus norvegicus |
Activity Data Samples
Top measurements by pChEMBL value
| Target | Type | Rel. | Value | Units | pChEMBL | Assay | PubMed |
|---|---|---|---|---|---|---|---|
| Voltage-dependent L-type calcium channel subunit alpha-1C | IC50 | = | 280.0 | nM | 6.55 | Inhibition of Cav1.2 calcium current measured using whole cell patch clamp in gu... | - |
| GABA-A receptor; anion channel | IC50 | = | 29500.0 | nM | 4.53 | The concentration required to inhibit 50% of binding of [35S]TBPS to Gamma-amino... | 9171876 |
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| 15646539 | 10.1016/s0399-8320(04)95062-2 | Unchecked | 11 |
| 15646539 | 10.1016/s0399-8320(04)95062-2 | NON-PROTEIN TARGET | 8 |
| 19764786 | 10.1021/jm901036q | Plasma | 4 |
| 18426954 | 10.1124/dmd.108.020479 | ADMET | 4 |
| 13215 | 10.1021/jm00211a010 | No relevant target | 3 |
| 21149540 | 10.1124/dmd.110.035998 | Brain | 3 |
| 9171876 | 10.1021/jm960733n | Mus musculus | 2 |
| 19764786 | 10.1021/jm901036q | ADMET | 2 |
| 533876 | 10.1021/jm00197a005 | No relevant target | 2 |
| - | 10.6019/CHEMBL4495565 | SARS-CoV-2 | 2 |
| 19445515 | 10.1021/jm900403j | Homo sapiens | 2 |
| 22899853 | 10.1124/dmd.112.046391 | Nucleic Acid | 2 |
| 22899853 | 10.1124/dmd.112.046391 | Cerebrospinal fluid | 2 |
| 22899853 | 10.1124/dmd.112.046391 | Plasma | 2 |
| 22899853 | 10.1124/dmd.112.046391 | ADMET | 2 |
| - | 10.6019/CHEMBL4651402 | SARS-CoV-2 | 2 |
| 6864729 | 10.1021/jm00361a014 | No relevant target | 2 |
| 9171876 | 10.1021/jm960733n | GABA-A receptor; anion channel | 2 |
| 22899853 | 10.1124/dmd.112.046391 | Brain | 2 |
| 19056282 | 10.1016/j.bmc.2008.11.040 | ADMET | 1 |
Data from ChEMBL 36 via Core Engine